Connect Biopharma Holdings Ltd. has released a corporate presentation detailing their advancements in drug development, specifically focusing on Rademikibart, an anti-IL-4Rα monoclonal antibody. The presentation highlights the company's experienced U.S. management team, assembled in the second half of 2024, which is dedicated to progressing Rademikibart for the treatment of eosinophilic driven respiratory diseases. The company has initiated Phase 2 studies for Rademikibart targeting acute exacerbations in asthma and COPD, with data expected in the first half of 2026. Market research indicates that Rademikibart could significantly outperform existing biologics like dupilumab, especially due to its potential use in acute exacerbation indications. The presentation outlines plans for ongoing studies and anticipates exclusivity for Rademikibart through at least 2040. Connect Biopharma retains global development and commercialization rights outside of greater China. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.